US Stock Market Move | Lilly (LLY.US) falls more than 4%, Shodis Biotech (GPCR.US) releases positive data on experimental weight-loss drug.

On Tuesday, the stock price of Eli Lilly & Company (LLY.US) opened low and fell, with the stock down over 4% to $948.76 as of the time of writing. On the news front, GPCR (GPCR.US) previously announced positive results for its experimental weight-loss drug aleniglipron. Data shows that patients experienced a weight loss of approximately 15% after 44 weeks of treatment. BMO Capital Markets analyst Evan Seigerman pointed out that the drug's efficacy "looks very competitive" and may even be superior to similar oral drugs from Novo Nordisk A/S Sponsored ADR Class B (NVO.US) and Eli Lilly. GPCR plans to initiate late-stage studies in the second half of 2026 using a "low and slow" dose titration method to prevent gastrointestinal side effects.